TP‐0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy

[1]  S. Jason,et al.  Neuroblastoma , 2018, Definitions.

[2]  F. Berthold,et al.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. , 2017, The Cochrane database of systematic reviews.

[3]  Marek J. Łos,et al.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets , 2017, Autophagy.

[4]  G. Tonini,et al.  Neuroblastoma treatment in the post-genomic era , 2017, Journal of Biomedical Science.

[5]  G. Gatta,et al.  Neuroblastoma (Peripheral neuroblastic tumours). , 2016, Critical reviews in oncology/hematology.

[6]  T. Eckschlager,et al.  Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma , 2016, PloS one.

[7]  G. Tonini,et al.  Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy? , 2016, Cancer Cell International.

[8]  D. Bearss,et al.  Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies , 2016 .

[9]  D. Bearss,et al.  Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis , 2016, Development.

[10]  Y. Assaraf,et al.  Could drugs inhibiting the mevalonate pathway also target cancer stem cells? , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  U. McDermott,et al.  Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination , 2016, Cancer cell.

[12]  R. Amaravadi,et al.  Emerging strategies to effectively target autophagy in cancer , 2016, Oncogene.

[13]  G. Tonini,et al.  Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells , 2015, Oncotarget.

[14]  N. Gray,et al.  ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT , 2015, Oncogene.

[15]  Asier Unciti-Broceta,et al.  AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. , 2015, Journal of medicinal chemistry.

[16]  Simon C Watkins,et al.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.

[17]  O. Delattre,et al.  Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis , 2015, Clinical Cancer Research.

[18]  T. Shanafelt,et al.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors , 2015, Clinical Cancer Research.

[19]  P. Ramani,et al.  Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma , 2015, Histopathology.

[20]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[21]  F. Penault-Llorca,et al.  Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy , 2014, Oncogene.

[22]  M. Cobb,et al.  Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK , 2014, Proceedings of the National Academy of Sciences.

[23]  L. Su,et al.  Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior , 2014, Oncotarget.

[24]  D. Burks,et al.  Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor , 2013, PloS one.

[25]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[26]  H. Spaink,et al.  Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model , 2012, The Journal of pathology.

[27]  G. Garcia-Manero,et al.  Notch pathway activation induces neuroblastoma tumor cell growth arrest , 2012, Pediatric blood & cancer.

[28]  V. Korshunov.  Axl-dependent signalling: a clinical update. , 2012, Clinical science.

[29]  T. Kamijo.  Role of stemness-related molecules in neuroblastoma , 2012, Pediatric Research.

[30]  Anupam Verma,et al.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. , 2011, ACS medicinal chemistry letters.

[31]  D. Bearss,et al.  Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.

[32]  T. Nakamura,et al.  CD133 suppresses neuroblastoma cell differentiation via signal pathway modification , 2011, Oncogene.

[33]  G. V. Chaitanya,et al.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration , 2010, Cell Communication and Signaling.

[34]  Joe W. Gray,et al.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment , 2010, Breast Cancer Research and Treatment.

[35]  D. Meek,et al.  Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. , 2010, Cellular signalling.

[36]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[37]  G. Feldmann,et al.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.

[38]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[39]  T. Fojo,et al.  Commentary: Novel therapies for cancer: why dirty might be better. , 2008, The oncologist.

[40]  J. Maris,et al.  Prevalence and functional consequence of PHOX2B mutations in neuroblastoma , 2008, Oncogene.

[41]  S. L. Gonias,et al.  High-resolution imaging of the dynamic tumor cell–vascular interface in transparent zebrafish , 2007, Proceedings of the National Academy of Sciences.

[42]  X. Bustelo,et al.  GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[43]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[44]  D. Green,et al.  Analysis of DNA fragmentation using agarose gel electrophoresis. , 2006, CSH protocols.

[45]  M. Ihnat,et al.  A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. , 2005, Cancer letters.

[46]  N. Cheung,et al.  Characteristics of stem cells from human neuroblastoma cell lines and in tumors. , 2004, Neoplasia.

[47]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[48]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[49]  Stefano Iacobelli,et al.  The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration , 2002, Oncogene.

[50]  D. Stern,et al.  Chk2 Activation and Phosphorylation-Dependent Oligomerization , 2002, Molecular and Cellular Biology.

[51]  Gerry Shaw,et al.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[53]  Maria Teresa Santini,et al.  Three-Dimensional Spheroid Model in Tumor Biology , 1999, Pathobiology.

[54]  C. Kimmel,et al.  Stages of embryonic development of the zebrafish , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[55]  D. Huhn,et al.  Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. , 1994, Blood.

[56]  J. Drouin,et al.  Structure of the rat pro‐opiomelanocortin (POMC) gene , 1985, FEBS letters.

[57]  F. Berthold,et al.  Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation. , 2015, The Cochrane database of systematic reviews.

[58]  D. Chung,et al.  Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. , 2014, Journal of pediatric surgery.

[59]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[60]  Hao Jiang,et al.  Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. , 2012, Cellular signalling.

[61]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[62]  H. Ostergaard,et al.  Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell activation and function , 2005, Immunologic research.

[63]  G. Lonergan,et al.  Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. , 2002, Radiographics : a review publication of the Radiological Society of North America, Inc.

[64]  K. Zänker,et al.  Prevention of entrance into G2 cell cycle phase by mimosine decreases locomotion of cells from the tumor cell line SW480. , 2001, Cancer letters.